AnteoTech (ASX:ADO) FY2026 Results Highlight Commercialisation Focus Across Battery Materials and Life Sciences

Sonal Goyal

30 September 2026 02:07 PM AEST

AnteoTech (ASX:ADO) FY2026 Results Highlight Commercialisation Focus Across Battery Materials and Life Sciences

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

AnteoTech Ltd (ASX:ADO) reported FY2026 sales Revenue of A$467,589 compared with A$968,878 in FY2025, with the previous year including an additional Serum Institute of India payment of A$276,863.
Total revenue declined to A$3.13 million in FY2026 from A$3.46 million in FY2025.
Operating expenses excluding non-cash items reduced to A$6.86 million in FY2026 from A$8.45 million in FY2025.
The company continued commercial and validation activities across Advanced Battery Technologies and Life Sciences markets.

AnteoTech Ltd (ASX:ADO) is a developer and supplier of advanced chemical and material solutions for battery materials and life sciences markets. The company uses its proprietary chemical platform technology to develop products for global customers, including battery technologies such as Anteo X™, Anteo S™, Anteo C and Ultranode™ products, alongside life sciences solutions under its AnteoBind™ suite. At the time of writing, AnteoTech Ltd (ASX:ADO) shares were trading at A$0.015 on 30 September 2026.

FY2026 Financial Performance

AnteoTech reported sales revenue of A$467,589 for FY2026, compared with A$968,878 in FY2025. The company noted that FY2025 sales included an additional payment of A$276,863 from the Serum Institute of India, impacting the year-on-year comparison. A further A$134,138 sale to Serum Institute of India completed on 7 July 2026 is expected to be recognised in FY2027.

Total revenue, including sales and other income such as Research and Development tax rebates and interest, was A$3.13 million in FY2026. This compared with A$3.46 million in FY2025 and A$4.35 million in FY2024.

The company’s FY2026 results were accompanied by a Business update presentation covering financial performance, strategic progress and future commercial priorities.

Cost Management and Financial Position

AnteoTech reduced operating expenses during FY2026 as part of its financial management approach. Operating expenses excluding non-cash items such as depreciation, Amortisation and share-based payments decreased to A$6.86 million in FY2026, compared with A$8.45 million in FY2025 and A$10.89 million in FY2024.

The company reported a loss of A$5.38 million in FY2026, compared with a loss of A$6.76 million in FY2025. The reduction in reported losses reflected lower operating expenses during the period.

As at 30 June 2026, AnteoTech reported cash in bank of A$11.2 million. The company had 3,265.1 million shares on issue and 233.5 million unlisted options as at 23 September 2026.

Technology Portfolio and Commercial Activities

AnteoTech operates across two primary markets: Advanced Battery Technologies and Life Sciences. The company’s battery portfolio includes Ultranode 70, Ultranode 95, Ultranode X, Anteo X, Anteo S, Anteo C and SiMRAX technologies. Its Life Sciences portfolio includes AnteoBind and AnteoBind NXT solutions for applications including lateral flow, CLIA and ELISA diagnostic platforms.

During FY2026, AnteoTech continued product validation activities across its technology portfolio. The company highlighted Ultranode 95 testing programs, Ultranode X internal validation and Ultranode 70 commercial cell format evaluation through customer engagement activities.

The company also expanded its product portfolio with Anteo S, Anteo C and SiMRAX products within Advanced Battery Technologies, while continuing development activities in CLIA and ELISA applications within Life Sciences.

Commercial Pipeline and Strategic Priorities

AnteoTech continued engagement with customers, partners and distributors across multiple regions, including India, the United States, Europe, Japan and South Korea. The company reported activities including customer evaluations, Partnership discussions and product validation programs.

During FY2026, AnteoTech highlighted a five-year US$1.8 million contract with the Serum Institute of India, evaluation of AnteoBind NXT activated ELISA plate prototypes, SiMRAX customer trials and Ultranode 95 commercial scale-up validation activities.

For FY2027, the company identified sales conversion as a key priority. Areas of focus include converting customer evaluations into sales, progressing CLIA and ELISA market entry activities, advancing battery technology partnerships and supporting commercial pipeline development.

Risks and Uncertainties

AnteoTech remains exposed to risks associated with commercialisation timelines, customer adoption, research and development outcomes and the conversion of product evaluations into commercial sales. The company’s future financial performance may depend on the progress of its technology validation programs, partnership activities and ability to develop commercial markets.

Key Takeaways

AnteoTech Ltd (ASX:ADO) reported lower revenue in FY2026 compared with FY2025, partly reflecting the timing of prior Serum Institute of India payments, while reducing operating expenses and narrowing its reported loss. The company continued Investment in battery materials and life sciences technologies, with FY2027 priorities focused on commercial conversion, customer engagement and partnership development.

FAQs

Q: What does AnteoTech Ltd (ASX:ADO) do?

A: AnteoTech develops advanced chemical and material solutions for battery materials and life sciences markets.

Q: What was AnteoTech’s FY2026 sales revenue?

A: AnteoTech reported FY2026 sales revenue of A$467,589.

Q: Did AnteoTech reduce operating expenses in FY2026?

A: Yes. Operating expenses excluding non-cash items declined to A$6.86 million in FY2026.

Q: Which battery technologies are part of AnteoTech’s portfolio?

A: The company’s battery technology portfolio includes Ultranode products, Anteo X, Anteo S, Anteo C and SiMRAX.

Q: What are AnteoTech’s FY2027 priorities?

A: The company’s FY2027 priorities include converting customer evaluations into sales, progressing partnerships and supporting commercial pipeline development.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.